Daiichi Sankyo and MSD have announced the first subject dosing in the Phase III Ideate-Esophageal01 trial, assessing the safety and efficacy of ifinatamab deruxtecan (I-DXd) in individuals with ...

IHH Healthcare, supported by Mitsui, has increased its compensation claim against Daiichi Sankyo to $1.3 billion in the Tokyo District Court, related to the Fortis Healthcare acquisition.

Disclaimer: This article has been developed and funded by Daiichi Sankyo. Daiichi Sankyo has more than 120 years of experience and scientific expertise. In 2019, they entered the oncology market ...

AstraZeneca has begun a new agreement with Daiichi Sankyo to develop and market an antibody to treat cancer, worth up to $6 billion. The deal covers DS-1062, Daiichi Sankyo’s proprietary ...

Merck MRK and Japan’s Daiichi Sankyo announced the dosing of the first patient in the phase III IDeate-Esophageal01 study evaluating their B7-H3 directed DXd antibody-drug conjugate (ADC ...

(Image/Reuters) Northern TK Venture (NTK), a Singapore-based indirect arm of Malaysia’s IHH Healthcare, has raised its damages claims against Japanese pharma firm Daiichi Sankyo Company by ...

IHH Healthcare said on Tuesday its unit has filed a petition in a Tokyo court to revise damages sought from Japan's Daiichi Sankyo over its Fortis Healthcare stake buy to up to 109.3 billion rupees ...

The United States doubled tariffs on steel and aluminium imports on Wednesday, activating a hike in the duties on the imported metals to 50% from the 25% rate introduced in March. The day also ...

Malaysia's IHH had initially approached a Tokyo district court in November 2023, seeking an order directing Daiichi Sankyo to pay 20 billion yen as damages to NTK. The next hearing is scheduled ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic Carcinoma Twenty-nine patients were enrolled. The ORR was ...